Other products in the same Health Canada class (L04A, L04AA) — coverage varies; not interchangeable
Mycophenolate (Myfortic): general benefit
Apremilast (Otezla): not a benefit
Cladribine (Mavenclad): not a benefit
Azathioprine (Imuran): general benefit
Cyclosporine (Neoral): general benefit
Leflunomide (Arava): general benefit
15 more in the class list below
CellCept · DIN 02242145 · 200mg/mL · powder for oral suspension-175mL Pk
Limited Use — Reason for Use code 556 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 556 required
Write on scriptLU code 556 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 556
Reason for Use code 556
For patients who are unable to swallow or tolerate solid oral dosage forms.
Coverage limit:
LU Authorization Period: Indefinite
Savings card: innoviCares lists CellCept (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
CellCept · DIN 02242145
Manufacturer: Hoffmann-La Roche Limited; listing date 2005-02-22
Health Canada: Marketed since 2002-08-27 · brand CELLCEPT · ATC L04AA06 MYCOPHENOLIC ACID · form Powder for suspension · route Oral · ingredients MYCOPHENOLATE MOFETIL 200 MG/ML · company Hoffmann-la roche limited · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65823 · Verify on the e-Formulary ↗ (DIN 02242145)
Source record
DIN 02242145: CellCept
Raw flags: sec12=Y, sec3=Y
Item: 920000510; group id 938; item number 2234; lccId 00131; manufacturer id HLR
Source form: Pd for Oral Susp-175mL Pk; strength: 200mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $358.0600; ministry $244.7025
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242145
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65823Interchangeable products
Mar-Mycophenolate Mofetil · DIN 02522233 · $244.7025
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242145
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mar-Mycophenolate Mofetil · DIN 02522233 · 200mg/mL · powder for oral suspension-175mL Pk
Limited Use — Reason for Use code 556 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 556 required
Write on scriptLU code 556 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 556
Reason for Use code 556
For patients who are unable to swallow or tolerate solid oral dosage forms.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Mar-Mycophenolate Mofetil · DIN 02522233
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2022-03-31
Health Canada: Marketed since 2022-02-03 · brand MAR-MYCOPHENOLATE MOFETIL · ATC L04AA06 MYCOPHENOLIC ACID · form Powder for suspension · route Oral · ingredients MYCOPHENOLATE MOFETIL 200 MG/ML · company Marcan pharmaceuticals inc · schedule Prescription
Mar-Mycophenolate Mofetil: Formulary list price $244.7025/unit (unit not stated in source; not the patient's cost)
Ministry pays: $244.7025 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101138 · Verify on the e-Formulary ↗ (DIN 02522233)
Source record
DIN 02522233: Mar-Mycophenolate Mofetil
Raw flags: sec12=Y, sec3=Y
Item: 920000510; group id 938; item number 2234; lccId 00131; manufacturer id MAR
Source form: Pd for Oral Susp-175mL Pk; strength: 200mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $244.7025; ministry $244.7025
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02522233
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101138Interchangeable products
CellCept · DIN 02242145 · $244.7025
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02522233
Shortage record checked 2026-09-13T08:10:21.292534+00:00
CellCept · DIN 02192748 · 250mg · capsule
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists CellCept (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
CellCept · DIN 02192748
Manufacturer: Hoffmann-La Roche Limited; listing date 1997-04-10
Health Canada: Marketed since 1995-12-31 · brand CELLCEPT · ATC L04AA06 MYCOPHENOLIC ACID · form Capsule · route Oral · ingredients MYCOPHENOLATE MOFETIL 250 MG · company Hoffmann-la roche limited · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19525 · Verify on the e-Formulary ↗ (DIN 02192748)
Source record
DIN 02192748: CellCept
Raw flags: sec3=Y
Item: 920000223; group id 937; item number 2233; lccId None; manufacturer id HLR
Source form: Cap; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $2.2833; ministry $0.3712
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02192748
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19525Interchangeable products
Apo-Mycophenolate · DIN 02352559 · $0.3712
Jamp-Mycophenolate Capsules · DIN 02386399 · $0.3712
Mycophenolate Mofetil · DIN 02457369 · $0.3712
Mycophenolate Mofetil Capsules · DIN 02383780 · $0.3712
Sandoz Mycophenolate Mofetil · DIN 02320630 · $0.3712
Teva-Mycophenolate · DIN 02364883 · $0.3712
Shortage status: resolved shortage (ended 2024-11-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02192748
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Mycophenolate Capsules · DIN 02386399 · 250mg · capsule
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Mycophenolate Capsules · DIN 02386399
Manufacturer: Jamp Pharma Corporation; listing date 2012-08-27
Health Canada: Marketed since 2025-10-07 · brand JAMP-MYCOPHENOLATE CAPSULES · ATC L04AA06 MYCOPHENOLIC ACID · form Capsule · route Oral · ingredients MYCOPHENOLATE MOFETIL 250 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Mycophenolate Capsules: Formulary list price $0.3712/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3712 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87198 · Verify on the e-Formulary ↗ (DIN 02386399)
Source record
DIN 02386399: Jamp-Mycophenolate Capsules
Raw flags: sec3=Y
Item: 920000223; group id 937; item number 2233; lccId None; manufacturer id JPC
Source form: Cap; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.3712; ministry $0.3712
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02386399
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87198Interchangeable products
Apo-Mycophenolate · DIN 02352559 · $0.3712
CellCept · DIN 02192748 · $0.3712
Mycophenolate Mofetil · DIN 02457369 · $0.3712
Mycophenolate Mofetil Capsules · DIN 02383780 · $0.3712
Sandoz Mycophenolate Mofetil · DIN 02320630 · $0.3712
Teva-Mycophenolate · DIN 02364883 · $0.3712
Shortage status: resolved shortage (ended 2025-10-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02386399
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mycophenolate Mofetil · DIN 02457369 · 250mg · capsule
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mycophenolate Mofetil · DIN 02457369
Manufacturer: Sanis Health Inc.; listing date 2020-08-28
Health Canada: Marketed since 2016-09-29 · brand MYCOPHENOLATE MOFETIL · ATC L04AA06 MYCOPHENOLIC ACID · form Capsule · route Oral · ingredients MYCOPHENOLATE MOFETIL 250 MG · company Sanis health inc · schedule Prescription
Mycophenolate Mofetil: Formulary list price $0.3712/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3712 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94442 · Verify on the e-Formulary ↗ (DIN 02457369)
Source record
DIN 02457369: Mycophenolate Mofetil
Raw flags: sec3=Y
Item: 920000223; group id 937; item number 2233; lccId None; manufacturer id SAI
Source form: Cap; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.3712; ministry $0.3712
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02457369
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94442Interchangeable products
Apo-Mycophenolate · DIN 02352559 · $0.3712
CellCept · DIN 02192748 · $0.3712
Jamp-Mycophenolate Capsules · DIN 02386399 · $0.3712
Mycophenolate Mofetil Capsules · DIN 02383780 · $0.3712
Sandoz Mycophenolate Mofetil · DIN 02320630 · $0.3712
Teva-Mycophenolate · DIN 02364883 · $0.3712
Shortage status: resolved shortage (ended 2020-11-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02457369
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mycophenolate Mofetil Capsules · DIN 02383780 · 250mg · capsule
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mycophenolate Mofetil Capsules · DIN 02383780
Manufacturer: Accord Healthcare Inc.; listing date 2012-06-26
Health Canada: Marketed since 2014-05-08 · brand ACH-MYCOPHENOLATE · ATC L04AA06 MYCOPHENOLIC ACID · form Capsule · route Oral · ingredients MYCOPHENOLATE MOFETIL 250 MG · company Accord healthcare inc · schedule Prescription
Mycophenolate Mofetil Capsules: Formulary list price $0.3712/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3712 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86955 · Verify on the e-Formulary ↗ (DIN 02383780)
Source record
DIN 02383780: Mycophenolate Mofetil Capsules
Raw flags: sec3=Y
Item: 920000223; group id 937; item number 2233; lccId None; manufacturer id ACH
Source form: Cap; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.3712; ministry $0.3712
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02383780
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86955Interchangeable products
Apo-Mycophenolate · DIN 02352559 · $0.3712
CellCept · DIN 02192748 · $0.3712
Jamp-Mycophenolate Capsules · DIN 02386399 · $0.3712
Mycophenolate Mofetil · DIN 02457369 · $0.3712
Sandoz Mycophenolate Mofetil · DIN 02320630 · $0.3712
Teva-Mycophenolate · DIN 02364883 · $0.3712
Shortage status: resolved shortage (ended 2026-04-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02383780
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Mycophenolate Mofetil · DIN 02320630 · 250mg · capsule
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Mycophenolate Mofetil · DIN 02320630
Manufacturer: Sandoz Canada Inc.; listing date 2012-01-19
Health Canada: Marketed since 2012-02-03 · brand SANDOZ MYCOPHENOLATE MOFETIL · ATC L04AA06 MYCOPHENOLIC ACID · form Capsule · route Oral · ingredients MYCOPHENOLATE MOFETIL 250 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Mycophenolate Mofetil: Formulary list price $0.3712/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3712 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80604 · Verify on the e-Formulary ↗ (DIN 02320630)
Source record
DIN 02320630: Sandoz Mycophenolate Mofetil
Raw flags: sec3=Y
Item: 920000223; group id 937; item number 2233; lccId None; manufacturer id SDZ
Source form: Cap; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.3712; ministry $0.3712
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02320630
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80604Interchangeable products
Apo-Mycophenolate · DIN 02352559 · $0.3712
CellCept · DIN 02192748 · $0.3712
Jamp-Mycophenolate Capsules · DIN 02386399 · $0.3712
Mycophenolate Mofetil · DIN 02457369 · $0.3712
Mycophenolate Mofetil Capsules · DIN 02383780 · $0.3712
Teva-Mycophenolate · DIN 02364883 · $0.3712
Shortage status: resolved shortage (ended 2020-06-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02320630
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Mycophenolate · DIN 02364883 · 250mg · capsule
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Mycophenolate · DIN 02364883
Manufacturer: Teva Canada Limited; listing date 2012-01-19
Health Canada: Marketed since 2017-08-08 · brand TEVA-MYCOPHENOLATE · ATC L04AA06 MYCOPHENOLIC ACID · form Capsule · route Oral · ingredients MYCOPHENOLATE MOFETIL 250 MG · company Teva canada limited · schedule Prescription
Teva-Mycophenolate: Formulary list price $0.3712/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3712 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84976 · Verify on the e-Formulary ↗ (DIN 02364883)
Source record
DIN 02364883: Teva-Mycophenolate
Raw flags: sec3=Y
Item: 920000223; group id 937; item number 2233; lccId None; manufacturer id TEV
Source form: Cap; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.3712; ministry $0.3712
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02364883
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84976Interchangeable products
Apo-Mycophenolate · DIN 02352559 · $0.3712
CellCept · DIN 02192748 · $0.3712
Jamp-Mycophenolate Capsules · DIN 02386399 · $0.3712
Mycophenolate Mofetil · DIN 02457369 · $0.3712
Mycophenolate Mofetil Capsules · DIN 02383780 · $0.3712
Sandoz Mycophenolate Mofetil · DIN 02320630 · $0.3712
Shortage status: active shortage (reported 2026-06-10, last updated 2026-07-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02364883
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ach-Mycophenolate · DIN 02378574 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ach-Mycophenolate · DIN 02378574
Manufacturer: Accord Healthcare Inc.; listing date 2012-06-26
Health Canada: Marketed since 2023-03-28 · brand ACH-MYCOPHENOLATE · ATC L04AA06 MYCOPHENOLIC ACID · form Tablet · route Oral · ingredients MYCOPHENOLATE MOFETIL 500 MG · company Accord healthcare inc · schedule Prescription
Ach-Mycophenolate: Formulary list price $0.7423/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.7423 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86436 · Verify on the e-Formulary ↗ (DIN 02378574)
Source record
DIN 02378574: Ach-Mycophenolate
Raw flags: sec3=Y
Item: 920000339; group id 939; item number 2235; lccId None; manufacturer id ACH
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.7423; ministry $0.7423
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02378574
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86436Interchangeable products
Apo-Mycophenolate · DIN 02352567 · $0.7423
CellCept · DIN 02237484 · $0.7423
Jamp-Mycophenolate · DIN 02380382 · $0.7423
Mycophenolate Mofetil · DIN 02457377 · $0.7423
Sandoz Mycophenolate Mofetil · DIN 02313855 · $0.7423
Teva-Mycophenolate · DIN 02348675 · $0.7423
Shortage status: resolved shortage (ended 2026-04-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02378574
Shortage record checked 2026-09-13T08:10:21.292534+00:00
CellCept · DIN 02237484 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists CellCept (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
CellCept · DIN 02237484
Manufacturer: Hoffmann-La Roche Limited; listing date 2000-04-17
Health Canada: Marketed since 1998-11-11 · brand CELLCEPT · ATC L04AA06 MYCOPHENOLIC ACID · form Tablet · route Oral · ingredients MYCOPHENOLATE MOFETIL 500 MG · company Hoffmann-la roche limited · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60818 · Verify on the e-Formulary ↗ (DIN 02237484)
Source record
DIN 02237484: CellCept
Raw flags: sec3=Y
Item: 920000339; group id 939; item number 2235; lccId None; manufacturer id HLR
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $4.5666; ministry $0.7423
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02237484
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60818Interchangeable products
Ach-Mycophenolate · DIN 02378574 · $0.7423
Apo-Mycophenolate · DIN 02352567 · $0.7423
Jamp-Mycophenolate · DIN 02380382 · $0.7423
Mycophenolate Mofetil · DIN 02457377 · $0.7423
Sandoz Mycophenolate Mofetil · DIN 02313855 · $0.7423
Teva-Mycophenolate · DIN 02348675 · $0.7423
Shortage status: resolved shortage (ended 2024-03-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02237484
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Mycophenolate · DIN 02380382 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Mycophenolate · DIN 02380382
Manufacturer: Jamp Pharma Corporation; listing date 2012-08-27
Health Canada: Marketed since 2026-08-14 · brand JAMP-MYCOPHENOLATE · ATC L04AA06 MYCOPHENOLIC ACID · form Tablet · route Oral · ingredients MYCOPHENOLATE MOFETIL 500 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Mycophenolate: Formulary list price $0.7423/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.7423 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86619 · Verify on the e-Formulary ↗ (DIN 02380382)
Source record
DIN 02380382: Jamp-Mycophenolate
Raw flags: sec3=Y
Item: 920000339; group id 939; item number 2235; lccId None; manufacturer id JPC
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.7423; ministry $0.7423
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02380382
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86619Interchangeable products
Ach-Mycophenolate · DIN 02378574 · $0.7423
Apo-Mycophenolate · DIN 02352567 · $0.7423
CellCept · DIN 02237484 · $0.7423
Mycophenolate Mofetil · DIN 02457377 · $0.7423
Sandoz Mycophenolate Mofetil · DIN 02313855 · $0.7423
Teva-Mycophenolate · DIN 02348675 · $0.7423
Shortage status: active shortage (reported 2025-08-07, estimated to end 2026-03-31, last updated 2025-08-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02380382
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mycophenolate Mofetil · DIN 02457377 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mycophenolate Mofetil · DIN 02457377
Manufacturer: Sanis Health Inc.; listing date 2020-08-28
Health Canada: Marketed since 2016-09-29 · brand MYCOPHENOLATE MOFETIL · ATC L04AA06 MYCOPHENOLIC ACID · form Tablet · route Oral · ingredients MYCOPHENOLATE MOFETIL 500 MG · company Sanis health inc · schedule Prescription
Mycophenolate Mofetil: Formulary list price $0.7423/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.7423 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94443 · Verify on the e-Formulary ↗ (DIN 02457377)
Source record
DIN 02457377: Mycophenolate Mofetil
Raw flags: sec3=Y
Item: 920000339; group id 939; item number 2235; lccId None; manufacturer id SAI
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.7423; ministry $0.7423
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02457377
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94443Interchangeable products
Ach-Mycophenolate · DIN 02378574 · $0.7423
Apo-Mycophenolate · DIN 02352567 · $0.7423
CellCept · DIN 02237484 · $0.7423
Jamp-Mycophenolate · DIN 02380382 · $0.7423
Sandoz Mycophenolate Mofetil · DIN 02313855 · $0.7423
Teva-Mycophenolate · DIN 02348675 · $0.7423
Shortage status: resolved shortage (ended 2024-02-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02457377
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Mycophenolate Mofetil · DIN 02313855 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Mycophenolate Mofetil · DIN 02313855
Manufacturer: Sandoz Canada Inc.; listing date 2012-01-19
Health Canada: Marketed since 2012-02-03 · brand SANDOZ MYCOPHENOLATE MOFETIL · ATC L04AA06 MYCOPHENOLIC ACID · form Tablet · route Oral · ingredients MYCOPHENOLATE MOFETIL 500 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Mycophenolate Mofetil: Formulary list price $0.7423/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.7423 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79937 · Verify on the e-Formulary ↗ (DIN 02313855)
Source record
DIN 02313855: Sandoz Mycophenolate Mofetil
Raw flags: sec3=Y
Item: 920000339; group id 939; item number 2235; lccId None; manufacturer id SDZ
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.7423; ministry $0.7423
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02313855
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79937Interchangeable products
Ach-Mycophenolate · DIN 02378574 · $0.7423
Apo-Mycophenolate · DIN 02352567 · $0.7423
CellCept · DIN 02237484 · $0.7423
Jamp-Mycophenolate · DIN 02380382 · $0.7423
Mycophenolate Mofetil · DIN 02457377 · $0.7423
Teva-Mycophenolate · DIN 02348675 · $0.7423
Shortage status: resolved shortage (ended 2026-01-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02313855
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Mycophenolate · DIN 02348675 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Mycophenolate · DIN 02348675
Manufacturer: Teva Canada Limited; listing date 2012-01-19
Health Canada: Marketed since 2017-08-08 · brand TEVA-MYCOPHENOLATE · ATC L04AA06 MYCOPHENOLIC ACID · form Tablet · route Oral · ingredients MYCOPHENOLATE MOFETIL 500 MG · company Teva canada limited · schedule Prescription
Teva-Mycophenolate: Formulary list price $0.7423/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.7423 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83402 · Verify on the e-Formulary ↗ (DIN 02348675)
Source record
DIN 02348675: Teva-Mycophenolate
Raw flags: sec3=Y
Item: 920000339; group id 939; item number 2235; lccId None; manufacturer id TEV
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.7423; ministry $0.7423
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02348675
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83402Interchangeable products
Ach-Mycophenolate · DIN 02378574 · $0.7423
Apo-Mycophenolate · DIN 02352567 · $0.7423
CellCept · DIN 02237484 · $0.7423
Jamp-Mycophenolate · DIN 02380382 · $0.7423
Mycophenolate Mofetil · DIN 02457377 · $0.7423
Sandoz Mycophenolate Mofetil · DIN 02313855 · $0.7423
Shortage status: resolved shortage (ended 2026-05-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02348675
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Mycophenolate · DIN 02352559 · 250mg · capsule
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Mycophenolate · DIN 02352559
Manufacturer: Apotex Inc.; listing date 2012-01-19
Health Canada: Dormant since 2025-06-29 · brand APO-MYCOPHENOLATE · ATC L04AA06 MYCOPHENOLIC ACID · form Capsule · route Oral · ingredients MYCOPHENOLATE MOFETIL 250 MG · company Apotex inc · schedule Prescription
Apo-Mycophenolate: Formulary list price $0.3712/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3712 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83781 · Verify on the e-Formulary ↗ (DIN 02352559)
Source record
DIN 02352559: Apo-Mycophenolate
Raw flags: sec3=Y
Item: 920000223; group id 937; item number 2233; lccId None; manufacturer id APX
Source form: Cap; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.3712; ministry $0.3712
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02352559
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83781Interchangeable products
CellCept · DIN 02192748 · $0.3712
Jamp-Mycophenolate Capsules · DIN 02386399 · $0.3712
Mycophenolate Mofetil · DIN 02457369 · $0.3712
Mycophenolate Mofetil Capsules · DIN 02383780 · $0.3712
Sandoz Mycophenolate Mofetil · DIN 02320630 · $0.3712
Teva-Mycophenolate · DIN 02364883 · $0.3712
Shortage status: active shortage (reported 2023-12-05, last updated 2024-01-19) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02352559
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-06-29 — choose a marketed DIN from the same-category list.
Apo-Mycophenolate · DIN 02352567 · 500mg · tablet
General benefitDormant since 2025-04-18 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Mycophenolate · DIN 02352567
Manufacturer: Apotex Inc.; listing date 2012-01-19
Health Canada: Dormant since 2025-04-18 · brand APO-MYCOPHENOLATE · ATC L04AA06 MYCOPHENOLIC ACID · form Tablet · route Oral · ingredients MYCOPHENOLATE MOFETIL 500 MG · company Apotex inc · schedule Prescription
Apo-Mycophenolate: Formulary list price $0.7423/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.7423 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83782 · Verify on the e-Formulary ↗ (DIN 02352567)
Source record
DIN 02352567: Apo-Mycophenolate
Raw flags: sec3=Y
Item: 920000339; group id 939; item number 2235; lccId None; manufacturer id APX
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.7423; ministry $0.7423
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02352567
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83782Interchangeable products
Ach-Mycophenolate · DIN 02378574 · $0.7423
CellCept · DIN 02237484 · $0.7423
Jamp-Mycophenolate · DIN 02380382 · $0.7423
Mycophenolate Mofetil · DIN 02457377 · $0.7423
Sandoz Mycophenolate Mofetil · DIN 02313855 · $0.7423
Teva-Mycophenolate · DIN 02348675 · $0.7423
Shortage status: active shortage (reported 2023-12-05, last updated 2024-01-19) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02352567
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-04-18 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered
· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00
and 75 more
Full class listing
Related classes:
Same formulary class, not same indication: class membership alone does not establish equivalent uses.What the Health Canada label says it is for
1. Indications
CellCept® (mycophenolate mofetil) is indicated for:
Adults
• The prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic
transplants. CellCept should be used concomitantly with cyclosporine and corticosteroids.
• CellCept i.v. (mycophenolate mofetil hydrochloride for intravenous infusion) is an alternative
dosage form to CellCept capsules, tablets and oral suspension. CellCept i.v. should be administered
within 24 hours following transplantation. CellCept i.v. can be administered for up to 14 days;
patients should be switched to oral CellCept as soon as they can tolerate oral medication.
1.1. Pediatrics
• Pediatrics (2-18 years of age): CellCept is indicated for the prophylaxis of organ rejection in
pediatric patients (2 to 18 years) receiving allogeneic renal transplants. CellCept should be used
concomitantly with cyclosporine and corticosteroids.
1.2. Geriatrics
• No data are available to Health Canada; therefore, Health Canada has not authorized an indication
for geriatric use.
https://pdf.hres.ca/dpd_pm/00083512.PDF
PM date: 2026-02-11
Source product: CELLCEPT; DIN 02192748; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Teva-Mycophenolate · DIN 02364883
Shortage status: active shortage (reported 2026-06-10, last updated 2026-07-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02364883
Jamp-Mycophenolate · DIN 02380382
Shortage status: active shortage (reported 2025-08-07, estimated to end 2026-03-31, last updated 2025-08-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02380382
Apo-Mycophenolate · DIN 02352559
Shortage status: active shortage (reported 2023-12-05, last updated 2024-01-19) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02352559
Apo-Mycophenolate · DIN 02352567
Shortage status: active shortage (reported 2023-12-05, last updated 2024-01-19) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02352567
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)